ISLR Inhibitors
Chemical inhibitors of ISLR can interact with various signaling pathways to modulate the function of this protein. Marimastat, by inhibiting metalloproteinases, can alter the extracellular matrix environment, impacting the normal functioning and signaling of ISLR, which relies on cell-cell junctions. Similarly, LY294002 and Wortmannin act as potent inhibitors of PI3K, a kinase that plays a critical role in a number of cellular pathways. Their action can impair the PI3K/Akt pathway, where ISLR is implicated, thus inhibiting the phosphorylation of Akt and downstream signaling that ISLR may be involved in. This can have a direct effect on the functional role of ISLR within these pathways, which are crucial for cell growth and survival.
Further affecting the MAPK pathway, U0126 and PD98059 target MEK1/2 and prevent the activation of ERK1/2. These inhibitors can decrease the participation of ISLR in the MAPK/ERK pathway. SB203580 and SP600125 specifically inhibit p38 MAP kinase and JNK, respectively, with both being components of the MAPK signaling pathways. The use of SB203580 can disrupt the p38-mediated responses, while SP600125 can suppress JNK-mediated events, both of which could be regulated by ISLR. Additionally, AG490, a tyrosine kinase inhibitor, particularly of JAK2, can prevent the activation of STAT transcription factors and impede the signaling transduction processes involving ISLR. Lastly, PP2 and Dasatinib act as inhibitors of Src family tyrosine kinases and broad-spectrum tyrosine kinase, respectively, leading to decreased tyrosine phosphorylation of downstream signaling components, which may inhibit the functional role of ISLR in cellular adhesion, migration, and proliferation. These interactions underscore the complex network of pathways that ISLR is involved in and how these chemical inhibitors can modulate its function within these pathways.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat inhibits metalloproteinases, which are involved in the degradation of the extracellular matrix. ISLR, being a cell adhesion molecule, interacts with the extracellular matrix and cell surface receptors. Inhibition of metalloproteinases by Marimastat can alter the matrix environment, possibly disrupting the normal function and signaling of ISLR at cell-cell junctions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, a kinase involved in multiple signaling pathways. ISLR has been implicated in PI3K/Akt signaling. By inhibiting PI3K, LY294002 can reduce Akt phosphorylation and downstream signaling, which could impair the signaling cascades in which ISLR participates, leading to functional inhibition of ISLR's role in these pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 specifically inhibits MEK1/2, which are upstream activators of ERK1/2 in the MAPK pathway. ISLR has been shown to be involved in the MAPK signaling pathway. Inhibition of MEK1/2 by U0126 would lead to decreased activation of ERK1/2, which could diminish the involvement of ISLR in MAPK pathway signaling, functionally inhibiting ISLR's role. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is another MEK inhibitor, which prevents the activation of downstream ERK1/2. Since ISLR is linked to the MAPK pathway, blocking MEK could inhibit the functional role of ISLR in cell signaling and proliferation processes facilitated by this pathway, as the ERK-mediated signaling events that ISLR may influence would be impaired. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which is part of the MAPK pathway. As ISLR is associated with MAPK signaling, the inhibition of p38 MAP kinase can disrupt the p38-mediated cellular responses, leading to a functional inhibition of ISLR's role in stress response and cytokine production, as well as other processes regulated by p38 MAPK where ISLR may play a part. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, another component of the MAPK signaling pathways. ISLR's interaction with the MAPK pathway suggests that by inhibiting JNK, SP600125 could suppress the JNK-mediated events that ISLR may be involved in, functionally inhibiting ISLR's role in processes such as apoptosis and inflammation that are regulated by JNK signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. Given ISLR's involvement in PI3K/Akt signaling, Wortmannin can inhibit the phosphorylation of Akt, thereby impairing the PI3K/Akt pathway and functionally inhibiting the role of ISLR in this signaling cascade, which is critical for various cellular functions such as growth and survival. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $84.00 $329.00 $223.00 $87.00 | 35 | |
AG490 is a tyrosine kinase inhibitor, particularly of JAK2. ISLR has been implicated in pathways involving tyrosine kinase activity. By inhibiting JAK2, AG490 could prevent the activation of STAT transcription factors, which in turn could impede the signal transduction processes in which ISLR is involved, leading to its functional inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Since ISLR is associated with tyrosine kinase signaling, inhibition of Src family kinases by PP2 can lead to decreased tyrosine phosphorylation of downstream signaling components, thereby potentially inhibiting ISLR's functional role in processes such as cellular adhesion, migration, and proliferation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against Src family kinases. As ISLR is implicated in signal transduction involving Src family kinases, Dasatinib's inhibition of these kinases can lead to a functional inhibition of ISLR's role in mediating cell-cell interactions and signaling pathways that rely on tyrosine kinase activity. | ||||||